Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
The consortium of businesses intends to work with state regulators to protect consumers as interest from secondary market investors also grows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback